{
      "Rank": 311,
      "Acronym": [
            "INV555"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [],
      "ArmGroupInterventionName": [
            "Drug: imatinib mesylate"
      ],
      "ArmGroupLabel": [
            "imatinib mesylate"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01172548"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Approximately 95% of GISTs are positive for KIT (CD117)-the receptor for stem cell factor (SCF). GISTs are not responsive to conventional cytotoxic chemotherapy and disease often recurs even after complete resection with wide margins.\n\nImatinib mesylate (trade names: Glivec\u00ae and Gleevec\u00ae, imatinib, formerly STI571) is a signal transduction inhibitor targeting several protein-tyrosine kinases that are believed to play a role in the proliferation of tumor cells. In the Phase II study of imatinib [CSTI571B 2222] in 147 patients with recurrent or metastatic GIST, the partial response rates were 67% and 66% in patients treated at 400 mg/d and 600 mg/d, respectively. Skin rash and elevated transaminases were the most common reason for drug discontinuation. The most frequently reported AEs were mild nausea, vomiting, diarrhea, superficial edema (primarily periorbital or lower limb), myalgia and muscle cramps. Grade 3/4 events included fluid retention (pleural or pericardial effusions, ascites, and pulmonary edema), skin rash, liver toxicity and gastrointestinal (GI) hemorrhage. Myelosuppression (neutropenia and thrombocytopenia) was a consistent finding. Also, a tumor lysis-like syndrome occurred in some patients leading to gastrointestinal (GI) and/or intratumoral hemorrhage.\n\nIn a Phase 3, American College of Surgeons Oncology Group trial (ACOSOG Z9001) of adjuvant imatinib, imatinib significantly improved 1-year recurrence-free survival (RFS) compared with placebo.\n\nIn summary, clinical trials have shown that imatinib produces clinical benefit in most patients with unresectable or metastatic GIST and extends median survival from 19 to 57 months. Imatinib is the standard of care for advanced GIST and has received regulatory approval for the treatment of unresectable or metastatic GIST. Studies suggest that adjuvant imatinib for 1 year prolongs RFS in patients at high risk of recurrent disease and metastases following complete surgical resection of the primary GIST.\n\nImatinib is an appealing adjuvant therapy for resected GIST because:\n\nPatients with primary GIST have a high chance of tumor recurrence\nConventional adjuvant treatment modalities are ineffective\nImatinib specifically inhibits the Kit receptor which is constitutively activated in most GISTs\nImatinib inhibits the growth of Kit positive cells in vitro\nImatinib is highly effective in many patients with advanced GIST in a Phase II trial\nImatinib has been associated with minimal toxicity in patients with advanced GIST and in patients with chronic myelogenous leukemia (CML)\nImatinib may have its greatest impact on survival when there is minimal disease.\n\nPrimary\n\nTo assess Recurrence Free Survival Rate in patients with resected primary GIST who are treated with adjuvant imatinib for a duration of 2 years Secondary\nTo compare Recurrence Free Survival, Overall Survival, and Time to Recurrence of patients with resected primary GIST who are treated with adjuvant imatinib for a duration of 2 years with historical data To assess the safety of imatinib given as adjuvant therapy for 2 years in patients with resected primary GIST"
      ],
      "BriefTitle": [
            "Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "March 2014"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Gastrointestinal Stromal Tumors"
      ],
      "ConditionAncestorId": [
            "D000009369",
            "D000009372",
            "D000018204",
            "D000009370",
            "D000005770",
            "D000004067",
            "D000004066",
            "D000005767"
      ],
      "ConditionAncestorTerm": [
            "Neoplasms",
            "Neoplasms, Connective Tissue",
            "Neoplasms, Connective and Soft Tissue",
            "Neoplasms by Histologic Type",
            "Gastrointestinal Neoplasms",
            "Digestive System Neoplasms",
            "Digestive System Diseases",
            "Gastrointestinal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC04",
            "BC06",
            "BC17",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Neoplasms",
            "Digestive System Diseases",
            "Skin and Connective Tissue Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Gastrointestinal Stromal Tumors",
            "Gastrointestinal Stromal Tumors"
      ],
      "ConditionBrowseLeafId": [
            "M14002",
            "M24795",
            "M11469",
            "M19502",
            "M11467",
            "M8038",
            "M6408",
            "M8035",
            "M6407",
            "T2444"
      ],
      "ConditionBrowseLeafName": [
            "Recurrence",
            "Gastrointestinal Stromal Tumors",
            "Neoplasms, Connective Tissue",
            "Neoplasms, Connective and Soft Tissue",
            "Neoplasms by Histologic Type",
            "Gastrointestinal Neoplasms",
            "Digestive System Neoplasms",
            "Gastrointestinal Diseases",
            "Digestive System Diseases",
            "Gastrointestinal Stromal Tumors"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000046152"
      ],
      "ConditionMeshTerm": [
            "Gastrointestinal Stromal Tumors"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Prevention"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nHistologically proven diagnosis of primary GIST (without peritoneal or distant metastasis) with positive immunostaining for KIT (CD117);\nUndergone complete gross resection of a primary GIST within 70 days prior to enrollment (includes R0 [negative microscopic margins] and R1 [positive microscopic margins]);\nIntermediate or high risk of recurrence based on Corless criteria (Section 5.1):\n\nExclusion Criteria:\n\nPatient has received prior therapy with imatinib, or any other molecular targeted or biological therapy.\n\nOther protocol-defined inclusion/exclusion criteria may apply"
      ],
      "EnrollmentCount": [
            "132"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000970",
            "D000047428",
            "D000004791",
            "D000045504"
      ],
      "InterventionAncestorTerm": [
            "Antineoplastic Agents",
            "Protein Kinase Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action"
      ],
      "InterventionArmGroupLabel": [
            "imatinib mesylate"
      ],
      "InterventionBrowseBranchAbbrev": [
            "ANeo",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Antineoplastic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Must"
      ],
      "InterventionBrowseLeafId": [
            "M324",
            "M24973"
      ],
      "InterventionBrowseLeafName": [
            "Imatinib Mesylate",
            "Protein Kinase Inhibitors"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low"
      ],
      "InterventionDescription": [],
      "InterventionMeshId": [
            "D000068877"
      ],
      "InterventionMeshTerm": [
            "Imatinib Mesylate"
      ],
      "InterventionName": [
            "imatinib mesylate"
      ],
      "InterventionOtherName": [
            "STI571",
            "Gleevec/Glivec"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Resected GIST",
            "primary GIST",
            "tumor recurrence",
            "KIT receptor",
            "KIT positive",
            "advanced GIST",
            "minimal toxicity",
            "GIST"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 31, 2017"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 28, 2017"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Novartis Pharmaceuticals"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Alger",
            "Cairo",
            "Mansoura",
            "Ahmedabad",
            "Pune",
            "Mumbai",
            "New Delhi",
            "Amman",
            "Beirut",
            "Kazan",
            "Ekaterinburg",
            "Irkutsk",
            "Kursk",
            "Omsk",
            "St. Petersburg",
            "Riyadh",
            "Parktown",
            "Tainan 704",
            "Taipei",
            "Lin-Ko",
            "Niaosong Township",
            "Taichung",
            "Taipei",
            "Bangkok",
            "Bangkok",
            "Bangkok",
            "Songkla",
            "Tunis",
            "Ankara"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Algeria",
            "Egypt",
            "Egypt",
            "India",
            "India",
            "India",
            "India",
            "Jordan",
            "Lebanon",
            "Russian Federation",
            "Russian Federation",
            "Russian Federation",
            "Russian Federation",
            "Russian Federation",
            "Russian Federation",
            "Saudi Arabia",
            "South Africa",
            "Taiwan",
            "Taiwan",
            "Taiwan",
            "Taiwan",
            "Taiwan",
            "Taiwan",
            "Thailand",
            "Thailand",
            "Thailand",
            "Thailand",
            "Tunisia",
            "Turkey"
      ],
      "LocationFacility": [
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site",
            "Novartis Investigative Site"
      ],
      "LocationState": [
            "Gujrat",
            "Maharashtra",
            "Tatarstan Republic",
            "Taiwan ROC",
            "Taiwan, ROC"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "016000",
            "380009",
            "411 001",
            "400016",
            "110044",
            "1107 2020",
            "420029",
            "620036",
            "664035",
            "305035",
            "644013",
            "198255",
            "11211",
            "2193",
            "112",
            "33305",
            "83301",
            "40705",
            "10002",
            "10330",
            "10400",
            "10700",
            "90110",
            "1006",
            "06100"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Multi-center, Single Arm, Phase II Study of Adjuvant Imatinib (Glivec\u00ae) in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor ( GIST)"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Novartis"
      ],
      "OrgStudyId": [
            "CSTI571BIC08"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Novartis Pharmaceuticals"
      ],
      "OverallOfficialName": [
            "Novartis Pharmaceuticals"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "March 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Recurrence Free Survival Rate"
      ],
      "PrimaryOutcomeTimeFrame": [
            "2 years"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [
            "Morocco"
      ],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [
            "Compare Recurrence Free Survival Rate to historical controls",
            "Compare Overall Survival to historical controls",
            "Compare Time To Recurrence to historical controls",
            "Adverse Events",
            "Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol"
      ],
      "SecondaryOutcomeTimeFrame": [
            "2 years",
            "2 years",
            "2 years",
            "2 years",
            "2 years"
      ],
      "SeeAlsoLinkLabel": [
            "J Clin Oncol 30, 2012 (suppl; abstr e20514) (From 2012 ASCO Annual Meeting )"
      ],
      "SeeAlsoLinkURL": [
            "http://meetinglibrary.asco.org/content/92196-114"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 2008"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "May 2017"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "July 29, 2010"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "June 22, 2010"
      ],
      "StudyFirstSubmitQCDate": [
            "July 28, 2010"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}